Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer australia ltd (animal health) - sulfadiazine - geriatric - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - tonics, stimulants

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios infarma ltda. - dobesilato de calcio - dobesilato de calcio....500.00 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

innovata pharmaceuticals - tablet - not indicated - none

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

innovata pharmaceuticals - tablet - not indicated - none

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation. cordarone x intravenous may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. cordarone x intravenous should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone; colloidal anhydrous silica - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; benzyl alcohol; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone hhh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone hhh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone gh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone gh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.